Antimetabolites
Start with the big picture
Antimetabolites interfere with nucleotide production or become incorporated into genetic material, disrupting replication and, in some cases, RNA function. The lesson groups these drugs into folate antagonists, pyrimidine analogs, and purine analogs. It connects each group’s mechanisms to agents such as methotrexate, 5-fluorouracil, cytarabine, and 6-mercaptopurine, alongside selected cancer uses and adverse effects. Examples include marrow and gastrointestinal toxicity, methotrexate-related mucositis and nephrotoxicity, and cytarabine-associated cerebellar toxicity. The material also introduces supportive measures and clinically relevant distinctions, including leucovorin rescue and folate/B12 supplementation with pemetrexed. This preview provides a framework for organizing the drug classes; the full lesson develops the individual agents and resistance mechanisms in greater detail.
What you'll learn
- Explain why antimetabolites are most active during the S phase.
- Distinguish folate antagonists, pyrimidine analogs, and purine analogs by their mechanisms.
- Relate selected antimetabolites to their uses and characteristic toxicities.
- Identify supportive measures associated with methotrexate and pemetrexed.
- Describe the role of resistance mechanisms in antimetabolite therapy.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.